SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?


To: santhosh mohan who wrote (855)1/22/1998 10:26:00 PM
From: Haolin Ni  Read Replies (2) | Respond to of 3579
 
The reason is simple: GERN has no profitable products in hand, not to mention any thing in clinical trial.

It is not easy to transfer sientific discovery to a profitable drug as well as a diagnostic kit. That is reason it get nothing fron Boehringer Mannheim for the moment when they announced to Develop and
Commercialize New Class of Cancer Diagnostics last Dec.

Please read its chart of last three years, it tell you how the stock price moving. Hope what I said help you a bit.

Good luck!